Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 10/20 | 0.37 |
| ▸ | PPARA | Q07869 | 10/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855027 | 0.83 | HTT (0.41) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL2860527 | 0.83 | PPARG (0.35) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL2860523 | 0.83 | PPARG (0.35) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL6472746 | 0.81 | PTGS2 (0.37) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL6472749 | 0.81 | PTGS2 (0.37) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL2858257 | 0.76 | VDR (0.63) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL2858262 | 0.75 | VDR (0.43) | ALDH1A1HPGDHTTPPARGPPARA | |
| SCHEMBL2856305 | 0.75 | PPARG (0.37) | HPGDPPARGPPARAMAPT | |
| SCHEMBL7120865 | 0.71 | ALDH1A1 (0.40) | ALDH1A1MAPTTSHRKDM4E | |
| SCHEMBL1022007 | 0.71 | ALDH1A1 (0.42) | ALDH1A1HPGDHTTPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456160-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2010-01-20 | — | — | EP | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| EP-1456160-A2 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003050067-A2 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | ALDH1A1 151/4885HPGD 85/4885HTT 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.